These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 24341486)

  • 1. Role of fluorodeoxyglucose positron emission tomography (FDG PET)-computed tomography (CT) in the staging of bladder cancer.
    Goodfellow H; Viney Z; Hughes P; Rankin S; Rottenberg G; Hughes S; Evison F; Dasgupta P; O'Brien T; Khan MS
    BJU Int; 2014 Sep; 114(3):389-95. PubMed ID: 24341486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of 18F-FDG PET/CT scan compared to CT-scan alone for lymph node staging before radical cystectomy in patients with bladder cancer.
    Moussa M; Chakra MA; Saad W; Dellis A; Papatsoris A
    Urol Oncol; 2021 Dec; 39(12):833.e9-833.e17. PubMed ID: 34059435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pelvic Lymph Node Staging by Combined
    Pichler R; De Zordo T; Fritz J; Kroiss A; Aigner F; Heidegger I; Virgolini I; Horninger W; Uprimny C
    Clin Genitourin Cancer; 2017 Jun; 15(3):e387-e395. PubMed ID: 27601364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pilot Study of [
    Eulitt PJ; Altun E; Sheikh A; Wong TZ; Woods ME; Rose TL; Wallen EM; Pruthi RS; Smith AB; Nielsen ME; Whang YE; Kim WY; Godley PA; Basch EM; David GU; Ramirez J; Deal AM; Rathmell WK; Chen RC; Bjurlin MA; Lin W; Lee JK; Milowsky MI
    Clin Genitourin Cancer; 2020 Oct; 18(5):378-386.e1. PubMed ID: 32147364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of 18F-fluoro-2-deoxy-d-glucose (18F-FDG) PET/CT for lymph node assessment before radical cystectomy in bladder cancer patients.
    Longoni M; Scilipoti P; Re C; Rosiello G; Nocera L; Pellegrino F; Basile G; de Angelis M; Quarta L; Burgio G; Necchi A; Cigliola A; Chiti A; Picchio M; Salonia A; Briganti A; Montorsi F; Moschini M
    BJU Int; 2024 Oct; 134(4):636-643. PubMed ID: 38621771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy.
    Jeong IG; Hong S; You D; Hong JH; Ahn H; Kim CS
    Ann Surg Oncol; 2015 Sep; 22(9):3150-6. PubMed ID: 25634779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy.
    Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T
    Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography and computed tomography in staging bladder cancer: a single-institution study and a systematic review with meta-analysis.
    Soubra A; Hayward D; Dahm P; Goldfarb R; Froehlich J; Jha G; Konety BR
    World J Urol; 2016 Sep; 34(9):1229-37. PubMed ID: 26847182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrated analysis of
    Girard A; Rouanne M; Taconet S; Radulescu C; Neuzillet Y; Girma A; Beaufrere A; Lebret T; Le Stanc E; Grellier JF
    Eur Radiol; 2019 Aug; 29(8):4286-4293. PubMed ID: 30666449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
    Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
    Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Added Clinical Value of
    van Ginkel N; van Gennep EJ; Oosterbaan L; Greidanus J; Boellaard TN; Wondergem M; Vis AN; de Reijke TM; van Rhijn BWG; Mertens LS
    Clin Genitourin Cancer; 2023 Jun; 21(3):342-348. PubMed ID: 36918302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of Lymph Node Metastasis in Patients with Bladder Cancer using Maximum Standardised Uptake Value and
    Vind-Kezunovic S; Bouchelouche K; Ipsen P; Høyer S; Bell C; Bjerggaard Jensen J
    Eur Urol Focus; 2019 Jan; 5(1):90-96. PubMed ID: 28753817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative lymph-node staging of invasive urothelial bladder cancer with 18F-fluorodeoxyglucose positron emission tomography/computed axial tomography and magnetic resonance imaging: correlation with histopathology.
    Jensen TK; Holt P; Gerke O; Riehmann M; Svolgaard B; Marcussen N; Bouchelouche K
    Scand J Urol Nephrol; 2011 Mar; 45(2):122-8. PubMed ID: 21231796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diuretic 18F-FDG PET/CT imaging for detection and locoregional staging of urinary bladder cancer: prospective evaluation of a novel technique.
    Nayak B; Dogra PN; Naswa N; Kumar R
    Eur J Nucl Med Mol Imaging; 2013 Feb; 40(3):386-93. PubMed ID: 23179944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.
    Kibel AS; Dehdashti F; Katz MD; Klim AP; Grubb RL; Humphrey PA; Siegel C; Cao D; Gao F; Siegel BA
    J Clin Oncol; 2009 Sep; 27(26):4314-20. PubMed ID: 19652070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging fluorodeoxyglucose positron emission tomography/computed tomography for muscle-invasive bladder cancer: a nationwide population-based study.
    Richters A; van Ginkel N; Meijer RP; Wondergem M; Schoots I; Vis AN; Kiemeney LALM; van Rhijn BWG; Witjes JA; Aben KKH; Mertens LS
    BJU Int; 2023 Oct; 132(4):420-427. PubMed ID: 37246479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic efficacy of [11C]choline positron emission tomography/computed tomography compared with conventional computed tomography in lymph node staging of patients with bladder cancer prior to radical cystectomy.
    Maurer T; Souvatzoglou M; Kübler H; Opercan K; Schmidt S; Herrmann K; Stollfuss J; Weirich G; Haller B; Gschwend JE; Schwaiger M; Krause BJ; Treiber U
    Eur Urol; 2012 May; 61(5):1031-8. PubMed ID: 22196847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the impact of 18F-FDG-PET-CT on risk stratification and treatment adaptation for patients with muscle-invasive bladder cancer (EFFORT-MIBC): a phase II prospective trial.
    Verghote F; Poppe L; Verbeke S; Dirix P; Albersen M; De Meerleer G; Berghen C; Ost P; Villeirs G; De Visschere P; De Man K; De Maeseneer D; Rottey S; Van Praet C; Decaestecker K; Fonteyne V
    BMC Cancer; 2021 Oct; 21(1):1113. PubMed ID: 34663254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDG-PET/CT for response evaluation of invasive bladder cancer following neoadjuvant chemotherapy.
    van de Putte EEF; Vegt E; Mertens LS; Bruining A; Hendricksen K; van der Heijden MS; Horenblas S; van Rhijn BWG
    Int Urol Nephrol; 2017 Sep; 49(9):1585-1591. PubMed ID: 28674853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.